RBC Capital Steps Aside on Global Blood Therapeutics (GBT), 'Oxbryta Beat Confirms Value; With Solid Outcome'
Tweet Send to a Friend
RBC Capital analyst Gregory Renza downgraded Global Blood Therapeutics (NASDAQ: GBT) from Outperform to Sector Perform with a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
